CROSSPOINT Therapeutics Raises $2.4M for Antibody Tech

South Korean biotechnology firm CROSSPOINT Therapeutics has successfully closed a $2.4 million pre-Series A funding round, signaling significant investor confidence in its novel antibody platform. The capital infusion was co-led by prominent venture capital firms KUDOS Ventures and Soo Investment Capital, with participation from strategic backers Y-Biologics and BMI Korea. This funding will accelerate the development of the company's proprietary 'Stealth-Body' technology, designed to enhance the therapeutic index of antibody-based treatments.

The core innovation behind Stealth-Body lies in its ability to mitigate the off-target effects often associated with antibody-drug conjugates (ADCs) and immunotherapies. By strategically modifying antibody structures to reduce unwanted interactions with immune system components – a process known as Fc silencing – CROSSPOINT aims to deliver more precise therapeutic action and improve patient safety profiles. This approach addresses a critical unmet need in oncology and other therapeutic areas where antibody therapies are increasingly prevalent.

The global market for ADCs alone is projected to reach tens of billions of dollars in the coming years, driven by advancements in conjugation chemistry and targeted delivery systems. CROSSPOINT's technology positions it to capture a share of this expanding market by offering a foundational improvement to antibody design, potentially making existing therapies safer and enabling the development of new ones.

Operating from the government-backed Hongcheon National Antibody Cluster in Gangwon Province, CROSSPOINT Therapeutics has benefited from a supportive ecosystem. The cluster provides essential research infrastructure and administrative aid, fostering an environment conducive to biotech innovation. This regional support underscores a growing national initiative in South Korea to cultivate a robust biopharmaceutical sector.

With the newly acquired funds, CROSSPOINT Therapeutics plans to initiate preliminary toxicity studies in primates within the current year. The primary objective is to generate compelling data demonstrating superior Therapeutic Index results, a crucial benchmark for international technology licensing. Achieving strong outcomes in these studies will serve as a key validation of the Stealth-Body platform's potential to outperform conventional antibody engineering methods.

The successful fundraising round also highlights the strategic importance of the Hongcheon cluster as a launchpad for emerging biotech enterprises. Local authorities have expressed commitment to further enhancing research facilities and researcher living conditions, with the overarching goal of establishing Hongcheon as a national center for novel drug discovery and development. This vision aligns with broader trends in the pharmaceutical industry, which increasingly relies on specialized innovation hubs.